Poly Medicure Share Price
Sector: Medical Equipment & Supplies
2259.25 -27.25 (-1.19%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2239.65
Today’s High
2307.35
52 Week Low
1590.25
52 Week High
3350.00
2258.60 -26.20 (-1.15%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2240.00
Today’s High
2306.10
52 Week Low
1585.60
52 Week High
3357.80
Key Metrics
- Market Cap (In Cr) 22892.01
- Beta 0.53
- Div. Yield (%) 0.15
- P/B 8.27
- TTM P/E 65.16
- Sector P/E 24.94
- D/E 0
- Open Price 2284.4
- Prev Close 2286.5
Poly Medicure Analysis
Price Analysis
-
1 Week-6.13%
-
3 Months10.96%
-
6 Month-18.83%
-
YTD-13.64%
-
1 Year27.01%
Risk Meter
- 43% Low risk
- 43% Moderate risk
- 43% Balanced Risk
- 43% High risk
- 43% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 0.00
- 1
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0.00
- 0.00
- 1
- 1
- Sell
- 2
- 2
- 1
- 1
- Strong Sell
- 1
- 1
- 0.00
- 0.00
- Total
- 4
- 5
- 4
- 4
Poly Medicure News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
2 min read . 07 Mar 2025Indian medtech firms eye exports as established MNCs dominate local market
4 min read . 27 Dec 2024Medical devices maker Poly Medicure to focus on exports amid geopolitical shift
4 min read . 24 Dec 2024Stocks to buy: Two stock recommendations from MarketSmith India for 11 December
2 min read . 11 Dec 2024Poly Medicure Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 1669.83
- Selling/ General/ Admin Expenses Total
- 301.53
- Depreciation/ Amortization
- 82.64
- Other Operating Expenses Total
- 336.2
- Total Operating Expense
- 1299.63
- Operating Income
- 370.2
- Net Income Before Taxes
- 452.52
- Net Income
- 338.56
- Diluted Normalized EPS
- 34.11
- Period
- 2025
- Total Assets
- 3192.45
- Total Liabilities
- 426.79
- Total Equity
- 2765.66
- Tangible Book Valueper Share Common Eq
- 267.5
- Period
- 2025
- Cashfrom Operating Activities
- 240.42
- Cashfrom Investing Activities
- -1194.28
- Cashfrom Financing Activities
- 950.51
- Net Changein Cash
- -3.35
- Period
- 2024
- Total Revenue
- 1375.8
- Selling/ General/ Admin Expenses Total
- 382.41
- Depreciation/ Amortization
- 63.91
- Other Operating Expenses Total
- 11.56
- Total Operating Expense
- 1078.56
- Operating Income
- 297.23
- Net Income Before Taxes
- 344.27
- Net Income
- 258.26
- Diluted Normalized EPS
- 26.64
- Period
- 2024
- Total Assets
- 1858.67
- Total Liabilities
- 388.62
- Total Equity
- 1470.05
- Tangible Book Valueper Share Common Eq
- 147.59
- Period
- 2024
- Cashfrom Operating Activities
- 266.08
- Cashfrom Investing Activities
- -240.94
- Cashfrom Financing Activities
- -20.15
- Net Changein Cash
- 4.99
- Period
- 2023
- Total Revenue
- 1115.23
- Selling/ General/ Admin Expenses Total
- 314.24
- Depreciation/ Amortization
- 57.12
- Other Operating Expenses Total
- 8.16
- Total Operating Expense
- 906.69
- Operating Income
- 208.54
- Net Income Before Taxes
- 237.49
- Net Income
- 179.28
- Diluted Normalized EPS
- 18.66
- Period
- 2023
- Total Assets
- 1577.21
- Total Liabilities
- 335.58
- Total Equity
- 1241.63
- Tangible Book Valueper Share Common Eq
- 124.19
- Period
- 2023
- Cashfrom Operating Activities
- 190.83
- Cashfrom Investing Activities
- -179.02
- Cashfrom Financing Activities
- -12.51
- Net Changein Cash
- -0.7
- Period
- 2022
- Total Revenue
- 923.06
- Selling/ General/ Admin Expenses Total
- 249.18
- Depreciation/ Amortization
- 53.87
- Other Operating Expenses Total
- 8.78
- Total Operating Expense
- 763.91
- Operating Income
- 159.15
- Net Income Before Taxes
- 195.24
- Net Income
- 146.51
- Diluted Normalized EPS
- 15.23
- Period
- 2022
- Total Assets
- 1376.83
- Total Liabilities
- 289.35
- Total Equity
- 1087.48
- Tangible Book Valueper Share Common Eq
- 108.11
- Period
- 2022
- Cashfrom Operating Activities
- 123.47
- Cashfrom Investing Activities
- -85.33
- Cashfrom Financing Activities
- -35.34
- Net Changein Cash
- 2.8
- Period
- 2021
- Total Revenue
- 786.47
- Selling/ General/ Admin Expenses Total
- 215.91
- Depreciation/ Amortization
- 47.44
- Other Operating Expenses Total
- 6.51
- Total Operating Expense
- 619.56
- Operating Income
- 166.91
- Net Income Before Taxes
- 180.05
- Net Income
- 135.87
- Diluted Normalized EPS
- 15.24
- Period
- 2021
- Total Assets
- 1223.73
- Total Liabilities
- 258.16
- Total Equity
- 965.57
- Tangible Book Valueper Share Common Eq
- 95.34
- Period
- 2021
- Cashfrom Operating Activities
- 118.73
- Cashfrom Investing Activities
- -435.58
- Cashfrom Financing Activities
- 316.95
- Net Changein Cash
- 0.1
- Period
- 2020
- Total Revenue
- 687.24
- Selling/ General/ Admin Expenses Total
- 219.5
- Depreciation/ Amortization
- 40.47
- Other Operating Expenses Total
- 6.1
- Total Operating Expense
- 563.71
- Operating Income
- 123.53
- Net Income Before Taxes
- 125.72
- Net Income
- 95.88
- Diluted Normalized EPS
- 10.85
- Period
- 2020
- Total Assets
- 767.32
- Total Liabilities
- 332.5
- Total Equity
- 434.82
- Tangible Book Valueper Share Common Eq
- 43.38
- Period
- 2020
- Cashfrom Operating Activities
- 130.51
- Cashfrom Investing Activities
- -109.46
- Cashfrom Financing Activities
- -20.51
- Net Changein Cash
- 0.54
- Period
- 2025-03-31
- Total Revenue
- 440.83
- Selling/ General/ Admin Expenses Total
- 78.89
- Depreciation/ Amortization
- 21.03
- Other Operating Expenses Total
- 88.47
- Total Operating Expense
- 342.4
- Operating Income
- 98.43
- Net Income Before Taxes
- 122.85
- Net Income
- 91.83
- Diluted Normalized EPS
- 9.25
- Period
- 2025-03-31
- Total Assets
- 3192.45
- Total Liabilities
- 426.79
- Total Equity
- 2765.66
- Tangible Book Valueper Share Common Eq
- 267.5
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 240.42
- Cashfrom Investing Activities
- -1194.28
- Cashfrom Financing Activities
- 950.51
- Net Changein Cash
- -3.35
- Period
- 2024-12-31
- Total Revenue
- 424.21
- Selling/ General/ Admin Expenses Total
- 77.89
- Depreciation/ Amortization
- 21.51
- Other Operating Expenses Total
- 81.27
- Total Operating Expense
- 331.18
- Operating Income
- 93.03
- Net Income Before Taxes
- 113.23
- Net Income
- 85.23
- Diluted Normalized EPS
- 8.48
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 420.02
- Selling/ General/ Admin Expenses Total
- 78.09
- Depreciation/ Amortization
- 20.85
- Other Operating Expenses Total
- 88.91
- Total Operating Expense
- 325.54
- Operating Income
- 94.47
- Net Income Before Taxes
- 117.98
- Net Income
- 87.45
- Diluted Normalized EPS
- 9.01
- Period
- 2024-09-30
- Total Assets
- 3052.26
- Total Liabilities
- 461
- Total Equity
- 2591.26
- Tangible Book Valueper Share Common Eq
- 250.38
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 111.81
- Cashfrom Investing Activities
- -1045.88
- Cashfrom Financing Activities
- 980.49
- Net Changein Cash
- 46.42
- Period
- 2024-06-30
- Total Revenue
- 384.78
- Selling/ General/ Admin Expenses Total
- 70.79
- Depreciation/ Amortization
- 19.65
- Other Operating Expenses Total
- 77.69
- Total Operating Expense
- 300.51
- Operating Income
- 84.27
- Net Income Before Taxes
- 98.46
- Net Income
- 74.04
- Diluted Normalized EPS
- 7.71
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 378.07
- Selling/ General/ Admin Expenses Total
- 69.44
- Depreciation/ Amortization
- 16.2
- Other Operating Expenses Total
- 75.94
- Total Operating Expense
- 297.69
- Operating Income
- 80.38
- Net Income Before Taxes
- 92.46
- Net Income
- 68.36
- Diluted Normalized EPS
- 7.13
- Period
- 2024-03-31
- Total Assets
- 1858.67
- Total Liabilities
- 388.62
- Total Equity
- 1470.05
- Tangible Book Valueper Share Common Eq
- 147.59
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 266.08
- Cashfrom Investing Activities
- -240.94
- Cashfrom Financing Activities
- -20.15
- Net Changein Cash
- 4.99
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Poly Medicure Technical
Moving Average
SMA
- 5 Day2342.81
- 10 Day2394.95
- 20 Day2468.87
- 50 Day2364.87
- 100 Day2364.68
- 300 Day2435.36
Poly Medicure Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Poly Medicure
- 2259.25
- -27.25
- -1.19
- 3350
- 1590.25
- 22892.01
- Mallcom (india)
- 1130
- -9.4
- -0.82
- 1780
- 937.2
- 703.52
- Prevest Denpro
- 486.4
- -0.95
- -0.19
- 686
- 351
- 583.05
- Nureca
- 255.9
- 5
- 1.99
- 447
- 198
- 255.9
- One Global Service Provider
- 250.35
- 4.9
- 2
- 407.6
- 89.18
- 177.87
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Poly Medicure
- 66.22
- 8.27
- 16.63
- 18.03
- Mallcom (india)
- 18.72
- 2.37
- 19.98
- 9.57
- Prevest Denpro
- 32.04
- 5.51
- 22.1
- 29.75
- Nureca
- 302.04
- 1.32
- 9.56
- 10.5
- One Global Service Provider
- 25.01
- 12.35
- 39.6
- 12.73
Poly Medicure Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 06-May-25
- Audited Results & Final Dividend
- 03-Feb-25
- Quarterly Results & Others
- 28-Oct-24
- Quarterly Results & ESOP
- 22-Jul-24
- Quarterly Results
- 29-Jun-24
- Others
- 17-May-24
- Audited Results & Final Dividend
- 08-Mar-24
- Others
- 31-Jan-24
- Quarterly Results
- 04-Nov-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 25-Jan-25
- 24-Dec-24
- POM
- 26-Sept-24
- 10-Sept-24
- AGM
- 05-Aug-24
- 04-Jul-24
- POM
- 28-Sept-23
- 06-Sept-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 06-May-25
- -
- -
- 3.5
- 17-May-24
- -
- 19-Sept-24
- 3
- 09-May-23
- -
- 21-Sept-23
- 3
- 24-May-22
- -
- 16-Sept-22
- 2.5
- 24-May-21
- -
- 16-Sept-21
- 2.5


